Notice: This application will enforce Multi-factor authentication (MFA) for NIH users beginning the evening of Wed Aug 3rd.
NIH | National Cancer Institute | NCI Wiki  

Diagnosis/Pathology:  Round 5


Diagnosis NCI CRF Standards created on October 19th, 2018

Diagnosis NCI CRF Standards created on June 11th, 2018

Diagnosis NCI CRF Standards created on December 9th, 2013

Changes made from December 9, 2013 to October 19th, 2018

ModuleCDECDE Public IDChange

Updates made based on finalized community review process

Location of Tumor




CDE 2856440 - Added additional value

  1. Skin/Subcutaneous

CDE 5936362 - Added additional values

  1. Colloid adenocarcinoma
  2. Combined hepatocellular-cholangiocarcinoma
  3. Desmoplastic melanoma
  4. Desmoplastic/Nodular Medulloblastoma 
  5. Ductal breast carcinoma in situ
  6. Enteric adenocarcinoma
  7. ETMR
  8. Giant Cell Glioblastoma 
  9. Gliosarcoma 
  10. Hepatoid adenocarcinoma
  11. High-grade neuroendocrine carcinoma (small cell type)
  12. Indeterminate MB
  13. Inflammatory myofibroblastic tumor
  14. Intraductal papillary mucinous neoplasm (IPMN, main duct/mixed)
  15. Intraductal papillary mucinous neoplasm (IPMN, Side duct)
  16. Intraductal papillary neoplasm with an associated invasive carcinoma
  17. Invasive adenocarcinoma arising from IPMN
  18. Invasive carcinoma arising in MCN
  19. Large Cell/Anaplastic MB
  20. Large Cell/Anaplastic Medulloblastoma 
  21. Large Cell/Anaplastic Medulloblastoma
  22. Lentigo maligna melanoma
  23. Medulloblastoma with Extensive Nodularity 
  24. Medulloepithelioma 
  25. Melanoma arising from blue nevus
  26. Melanoma arising in a giant congenital nevus
  27. Melanoma, NOS
  28. Micropapillary carcinoma
  29. Minimally invasive adenocarcinoma, mucinous
  30. Minimally invasive adenocarcinoma, nonmucinous
  31. Mixed acinar-ductal carcinoma
  32. Mixed acinar-neuroendocrine carcinoma
  33. Mixed adenoneuroendocrine carcinoma
  34. Mixed ductal-neuroendocrine carcinoma
  35. Moderately-differentiated neuroendocrine carcinoma
  36. Mucinous cystic neoplasm with an associated invasive carcinoma
  37. Mucinous cystic neoplasms (MCN)
  38. Neuroendocrine Carcinoma (poorly differentiated)
  39. Neuroendocrine carcinoma, large cell
  40. Neuroendocrine carcinoma, small cell
  41. Nevoid melanoma
  42. Nodular melanoma
  43. Pancreatoblastoma NOS
  44. Pilocytic Astrocytoma 
  45. Serrated Adenocarcinoma
  46. Signet ring Cell Carcinoma
  47. Small cell neuroendocrine carcinoma
  48. Solid adenocarcinoma
  49. Solid pseudopapillary neoplasm
  50. Superficial spreading melanoma
  51. Undifferentiated Carcinoma
  52. Well-differentiated neuroendocrine carcinoma


      Pilot workflow steps. 1) CTROC reviews and approves. 2) Biostatistician reviews and approves for Cooperative Groups. 3) A participant for each of the NCI cooperative groups approves any content that has changed since. 4) Working group reviews and responds to changes from community review and CBIIT staff review content to ensure the use of standards. 5) Module is distributed for community review. 6) Working group, with CBIIT curator matches data elements to all questions and achives consensus on final list of elements. 7) Working group reviews and partitions content as Mandatory, Conditional, Optional, or non-harmonized. 8) Working group, NCI Cooperative Groups and NCI divisions aggregate and identify common content to retain, resolves discrepancies, and achieves harmonization. 9) CBIIT staff collects existing CRFs, and creates and inventory of content.


CRF Stars:  Working Group Membership

* Represents working group leads


First Name

Last Name


4NeeshaDesaiEssex Management
9AndreaHwangUniversity of California, Irvine
11AngelaKummerowNational Marrow Donor Program
12BobLaneseCase Western University
13PatrickMcConnellSemantic Bits
15ElaineMotyka WelshRTOG
16DianeOliverWashington University
17DianePaulPatient Advocate
20FrankSpinaEssex Management
23MarkWatsonWashington University
24WesleyWigginsSemantic Bits
  • No labels